Emerging computational and pharmacological study of topiramate: A brief review

Abstract

Topiramate, a second-generation antiepileptic drug used to manage and treat epileptic seizures was approved by the FDA in 1996 as a solo or supplementary for the therapy of epilepsy. The frequency, severity, quality of life, and adverse events that topiramate has on epilepsy patients, including children and adolescents, are summarized in this review. The medication has a generally favorable safety profile and is well accepted, although monitoring the patient's medication, preventing its abuse, and improving patient outcomes all require knowledge. Despite the numerous scientific theories that surround the drug, more research into the uniqueness of medicine is required. This review will highlight the drug profile, synthesis, pharmacology, ADME properties, and computational study of topiramate.